Comprehensive preclinical pharmacology and pharmacodynamics evaluation bench & full range of animal models
KCI has established a comprehensive anti-infective R&D and service platform with both BSL-2 and ABSL-2 qualifications, forming the core of our infectious disease CRO services. The BSL-2 laboratory (approx. 200m²) supports work with cells, viruses, and bacteria, while the ABSL-2 facility (approx. 1,000m²) includes a 300m² small animal lab and a 700m² large animal lab. After nearly two years of internal R&D and external service delivery, this platform—central to our role as a vaccine/infectious disease CRO—has completed the filing for over 100 pathogenic microorganisms and successfully established various animal models for viral, bacterial, and fungal infectious diseases. We have partnered with over 20 R&D enterprises in human and veterinary vaccines and anti-infective therapies, leveraging our full suite of infectious disease CRO services to advance preclinical drug development and regulatory filing.
KCI Biotech is an experienced infectious disease CRO, providing comprehensive in vivo pharmacology and efficacy services for drug discovery and preclinical development. All studies are performed under GLP-compliant management by professionally trained staff with extensive project experience. Our infectious disease CRO services are designed to deliver scientific accuracy, safety, and reproducibility, supporting the pursuit of innovative therapies for infectious diseases and vaccine development.
Infectious diseases continue to pose significant global health challenges, with many pathological processes unable to be fully replicated in vitro. Animal models of infection are therefore indispensable for understanding disease mechanisms, evaluating drug and vaccine efficacy, and predicting clinical outcomes.
At KCI Biotech, our infectious disease models are carefully developed and validated to simulate human infectious conditions, enabling translational studies that bridge preclinical findings to clinical reality.
KCI Biotech provides a wide spectrum of infectious disease models covering viral, bacterial, and fungal pathogens. Each model is established using reproducible induction methods and standardized evaluation criteria.
Virus Attack Model
AAV-HBV1.3 Infection Model
Reproductive Tract Infection Model
Neuropathic Pain/Skin Herpes Model
Feline Infectious Peritonitis (FIP) Infection Model
Rabbit CRPV Virus-Induced Skin Papilloma Model
Feline Transmissible Abdominal Infection Model
Skin Wound Infection Model
Sepsis Model
Thigh Muscle Infection Model
Pneumonia Model
Vaginitis Model
Sepsis Model
Pneumonia Model
Additional infectious disease models are available upon request. Custom modeling and tailored evaluation endpoints can be provided based on sponsor needs.
As a vaccine/infectious disease CRO with a long-standing focus on infectious disease research, KCI Biotech combines expertise in virology, bacteriology, and immunology to support discovery and translational studies. Our team has deep experience with models for respiratory infections, systemic sepsis, dermatological infections, and vaccine efficacy evaluation.
We integrate in vivo imaging, biochemical, histopathological, and molecular analyses to evaluate therapeutic and vaccine efficacy across multi-level endpoints. This ensures data reliability and high translational relevance.
With over 1,000 domestic and international partnerships, KCI Biotech has established a strong reputation as a reliable contract organization for infectious disease research. Our efficient communication, transparent data management, and rapid study turnaround make us a trusted infectious diseases and vaccines CRO services provider for global clients.
From model selection to data interpretation, KCI Biotech provides comprehensive infectious disease CRO services that accelerate the development of safe and effective anti-infectives and vaccines.
Whether you’re working on antiviral agents, antibacterial therapies, vaccine candidates, or novel antifungal drugs, our validated animal models and experienced team ensure scientific accuracy and translational success.
Comprehensive preclinical drug development and service platform
Building A2, No, 8 Yanghua road, Suzhou industrial Park, Suzhou.P.R, china
